I added this as a comment in the long NIH TIL thread but I also wanted to add it as a post too.
A new biotech was announced today which among their plans are what appears to be commercialization of the NIH TIL trial our own Sleen is doing so well on. They haven't announce yet types of cancer they will try to go after (melanoma is a no-brainer) but getting it to commercial stage is a huge step forward for all cancer types responding. It is not your average biotech - it is fronted by very big business & science people in the field. Commercializing the TIL trial is what will be needed t to get it to the masses. The NIH can provide the proof-of-principle with trial heroes like Sleen but they can't handle & help large numbers of people. The immunotherapy wave continues to build! http://www.fiercebiotech.com/story/thir ... 2015-09-30